These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19484732)

  • 1. Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: a report of two patients.
    Bose P; Hussein KK; Terrell DR; Berger D; Rice L; George JN
    Am J Hematol; 2009 Jul; 84(7):459-61. PubMed ID: 19484732
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
    Taylor N; Melchardt T; Grundbichler M; Strasser M; Egle A; Greil R
    Ann Hematol; 2013 Jul; 92(7):1001-2. PubMed ID: 23269533
    [No Abstract]   [Full Text] [Related]  

  • 3. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
    Kuter DJ
    Annu Rev Med; 2009; 60():193-206. PubMed ID: 19642221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus.
    Alkaabi JK; Alkindi S; Riyami NA; Zia F; Balla LM; Balla SM
    Lupus; 2012 Dec; 21(14):1571-4. PubMed ID: 23161577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune thrombocytopenia and anticoagulation: the role of romiplostim in the early treatment.
    Cantoni N; Heizmann M; Bargetzi M
    Br J Haematol; 2012 Jun; 157(5):639-41. PubMed ID: 22329466
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors.
    Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
    Haematologica; 2018 Apr; 103(4):e169-e172. PubMed ID: 29242295
    [No Abstract]   [Full Text] [Related]  

  • 7. Overview of thrombopoietic agents in the treatment of thrombocytopenia.
    Kobos R; Bussel JB
    Clin Lymphoma Myeloma; 2008 Feb; 8(1):33-43. PubMed ID: 18501086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombopoietin receptor agonists can be used temporarily with patients suffering from refractory chronic lymphocytic leukemia-associated immunologic thrombocytopenia.
    Sinisalo M; Sankelo M; Itälä-Remes M
    Leuk Lymphoma; 2011 Apr; 52(4):724-5. PubMed ID: 21323511
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombopoietin-receptor agonists for immune thrombocytopenia.
    Jansen AJ; Swart RM; te Boekhorst PA
    N Engl J Med; 2011 Dec; 365(23):2240-1. PubMed ID: 22150056
    [No Abstract]   [Full Text] [Related]  

  • 10. Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia.
    D'Arena G; Cascavilla N
    Leuk Lymphoma; 2011 Apr; 52(4):701-4. PubMed ID: 21171868
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists.
    Lee EJ; Seshadri M; Bussel JB
    Am J Hematol; 2021 Oct; 96(10):E373-E376. PubMed ID: 34152624
    [No Abstract]   [Full Text] [Related]  

  • 12. Romiplostim reverts the thrombocytopenia in dengue hemorrhagic fever.
    Rodríguez-Mejorada SM; Rosel-Gómez CG; Rosado-Castro RA; Domingo-Padilla MA; Ruiz-Delgado GJ
    Hematol Oncol Stem Cell Ther; 2011; 4(1):48-9. PubMed ID: 21460608
    [No Abstract]   [Full Text] [Related]  

  • 13. A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia.
    Miao J; Leblebjian H; Scullion B; Parnes A
    Am J Hematol; 2018 Aug; 93(4):E86-E88. PubMed ID: 29274130
    [No Abstract]   [Full Text] [Related]  

  • 14. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
    Imbach P; Crowther M
    N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
    [No Abstract]   [Full Text] [Related]  

  • 15. Romiplostim in the management of thrombocytopenia in a patient with autoimmune hepatitis.
    Gangireddy VG; Coleman TA; Nabh A; Sridhar S
    Dig Dis Sci; 2012 Sep; 57(9):2466-72. PubMed ID: 22828806
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia.
    Aslam MI; Cardile AP; Crawford GE
    J Int Assoc Provid AIDS Care; 2014; 13(1):22-3. PubMed ID: 24036490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of complex immune-mediated thrombocytopenia to romiplostim in the setting of allogeneic stem cell transplantation for chronic myelogenous leukemia.
    Bollag RJ; Sterett M; Reding MT; Key NS; Cohn CS; Ustun C
    Eur J Haematol; 2012 Oct; 89(4):361-4. PubMed ID: 22775392
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.
    Platzbecker U; Sekeres MA; Kantarjian H; Giagounidis A; Mufti GJ; Jia C; Yang AS; Fenaux P
    Leukemia; 2014 Dec; 28(12):2418-21. PubMed ID: 25179731
    [No Abstract]   [Full Text] [Related]  

  • 19. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
    Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
    Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
    [No Abstract]   [Full Text] [Related]  

  • 20. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies.
    Jacobson AE; Shah N; Setty BA
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28150377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.